|Bid||1.4800 x 1000|
|Ask||1.4900 x 1300|
|Day's Range||1.4300 - 1.4900|
|52 Week Range||1.4200 - 4.4000|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2019 - Nov 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...
Chimerix (CMRX), a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases, today announces an exclusive global license agreement with SymBio Pharmaceuticals, Ltd (SymBio), under which SymBio has exclusively licensed the worldwide rights to develop, manufacture and commercialize brincidofovir in all human indications, excluding the prevention and treatment of smallpox. Moving forward, SymBio will be responsible for all future development and commercialization as well as manufacturing costs associated with brincidofovir in the licensed indications.
DURHAM, N.C., Sept. 27, 2019 -- Chimerix (NASDAQ:CMRX) today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming 2019 Cantor.
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...
Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Pipeline Transformed with Acquisition of Global Rights to Late Stage Oncology Asset (CX-01) with Fast Track and Orphan Drug Designation Phase 3 Trial of CX-01 in Front-Line.
Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chimerix (CMRX), today announced the completion of an exclusive worldwide license of CX-01 from Cantex Pharmaceuticals, Inc. Chimerix intends to move quickly into Phase 3 development of CX-01 for the treatment of Acute Myeloid Leukemia (AML) in the first-line setting. “We are pleased to have made such rapid progress in repositioning the company and transforming our pipeline with this important cancer therapy.
Does Chimerix Inc (NASDAQ:CMRX) represent a good buying opportunity at the moment? Let’s quickly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Durham, North Carolina-based company said it had a loss of 35 cents per share. The biopharmaceutical company posted revenue of $2.4 million in the period. The company's shares closed at $2.68. A year ...
– Reports Positive Top-line Survival Data from Pivotal Mouse Study as Key Milestone on Path to Smallpox Regulatory Submission – – Plan to Focus on Execution of Smallpox.
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Chimerix, Inc. (NASDAQ: CMRX ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
DURHAM, N.C., May 02, 2019 -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel antivirals to address life-threatening viral infections, today.
Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in Chimerix, Inc. (NASDAQ:CMRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of volatility. Modern finance theory considers volatili...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 8) Alector Inc (NASDAQ: ALEC ) Denali Therapeutics Inc ...
Chimerix (CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announces the appointment of Michael A. Sherman, former Chief Executive Officer of Endocyte, Inc., as Chief Executive Officer of Chimerix, effective immediately.